SOURCE: Generex Biotechnology Corporation

October 26, 2006 11:15 ET

Generex Biotechnology to Make Podium Presentation at the World Congress on Controversies in Obesity, Diabetes and Hypertension

TORONTO -- (MARKET WIRE) -- October 26, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, will make a podium presentation at The World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) ( to be held in Berlin, Germany, October 26 - 29, 2006. The presentation relates to clinical studies in respect of Generex Oral-lyn™, the Company's proprietary oral insulin spray product designed to replace prandial insulin injections.

On October 27, 2006, Dr. Bernstein will present a paper entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn™) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin." The paper was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.

In addition, the following Generex-sponsored study is the subject of a poster presentation at CODHy: "Generex Metformin Gum: An Alternative Method for Delivery of Biguanides," authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs.

Generex is also pleased to announce that Dr. Jaime Davidson, its Medical Director, will be participating in a pre-congress symposium on October 26, 2006 entitled "New Concepts in the Management of Type-2 Diabetes: a DPP-4 Inhibitor Pre-Symposium." Dr. Davidson will be making the symposium introduction with a talk entitled "Key Limitations in the Current Therapies for Type-2 Diabetes." Dr. Davidson will also be making the following additional presentations at CODHy: "Glycemic Targets in Clinical Practice: What should be the focus?," "Confronting Diabetes: The coronary heart disease (CHD) risk equivalent," and "Debate: Insulin analogues versus pump therapy in Type-2 Diabetes."

This congress will be focusing on two significant aspects of diabetes management which are the focus of the Generex product pipeline: prevention, and post-prandial glucose control.

The strong connection between obesity, diabetes, and hypertension is well recognized by the medical community yet their treatments were for many years unrelated. With all three conditions having reached epidemic proportions worldwide, their treatments as one field are now rapidly expanding. CODHy is an exclusive forum in which world eminent experts convene to share and compare their experiences with the goal of optimizing treatments for patients suffering from more than one of these common disorders. Over the years, the areas of obesity, diabetes, and hypertension have experienced an enormous expansion in clinical and basic data as well as tremendous growth in related technologies. Such growth has fueled a greater need to debate the many controversial issues and crystallize them into clinical conclusions. The CODHy Congress provides a forum to discuss and debate unresolved controversies, by allowing leading speakers ample time to present conflicts and their effects on patients, and the participating audience sufficient time to discuss and propose informed views. The Congress' goal is to provide answers to difficult controversial questions, allowing clinician to return to his practice with reliable, up-to-date scientific answers, based on the best existing evidence and expert opinion.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Contacts:
    Shayne Gilliatt
    Generex Biotechnology Corporation
    Phone: (800) 391-6755
    or (416) 364-2551

    Andrew Hellman
    CEOcast, Inc.
    Phone: (212) 732-4300

    Dolores Naney
    Rubenstein Public Relations
    Phone: (212) 843-8018